Protagenic Income Tax Expense from 2010 to 2024

PTIXW Stock  USD 0.01  0.0005  5.75%   
Protagenic Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense will likely drop to 1.90 in 2024. During the period from 2010 to 2024, Protagenic Therapeutics Income Tax Expense regression line of quarterly data had r-squared of  0.0003 and coefficient of variation of  146.53. View All Fundamentals
 
Income Tax Expense  
First Reported
1995-09-30
Previous Quarter
(1.00)
Current Value
2
Quarterly Volatility
796.6 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Very volatile
   Income Tax Expense   
       Timeline  

Protagenic Income Tax Expense Regression Statistics

Arithmetic Mean151,346
Coefficient Of Variation146.53
Mean Deviation191,581
Median101,000
Standard Deviation221,763
Sample Variance49.2B
Range686.8K
R-Value(0.02)
Mean Square Error52.9B
R-Squared0.0003
Significance0.95
Slope(832.23)
Total Sum of Squares688.5B

Protagenic Income Tax Expense History

2024 1.9
2023 2.0
202246.1 K
2021463.7 K
2020246.2 K
201915.9 K
2018486.8 K

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense 2.00  1.90 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.